Intuitive Surgical, Inc. (NASDAQ:ISRG - Get Free Report) EVP Mark Brosius sold 46 shares of the business's stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $444.38, for a total transaction of $20,441.48. Following the sale, the executive vice president directly owned 411 shares of the company's stock, valued at approximately $182,640.18. This trade represents a 10.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Mark Brosius also recently made the following trade(s):
- On Wednesday, November 18th, Mark Brosius sold 46 shares of Intuitive Surgical stock. The shares were sold at an average price of $430.63, for a total transaction of $19,808.98.
- On Wednesday, October 28th, Mark Brosius sold 61 shares of Intuitive Surgical stock. The shares were sold at an average price of $441.60, for a total transaction of $26,937.60.
- On Monday, October 26th, Mark Brosius sold 61 shares of Intuitive Surgical stock. The shares were sold at an average price of $451.75, for a total transaction of $27,556.75.
- On Friday, September 11th, Mark Brosius sold 25 shares of Intuitive Surgical stock. The shares were sold at an average price of $365.79, for a total value of $9,144.75.
- On Wednesday, September 9th, Mark Brosius sold 23 shares of Intuitive Surgical stock. The stock was sold at an average price of $350.20, for a total transaction of $8,054.60.
- On Tuesday, September 8th, Mark Brosius sold 46 shares of Intuitive Surgical stock. The stock was sold at an average price of $361.23, for a total value of $16,616.58.
- On Friday, August 21st, Mark Brosius sold 77 shares of Intuitive Surgical stock. The stock was sold at an average price of $375.57, for a total transaction of $28,918.89.
Intuitive Surgical Price Performance
NASDAQ:ISRG traded down $9.58 during trading hours on Wednesday, reaching $420.95. 2,213,548 shares of the company were exchanged, compared to its average volume of 2,435,968. The business has a 50 day moving average of $421.98 and a 200 day moving average of $428.75. The company has a market capitalization of $145.92 billion, a P/E ratio of 50.90, a P/E/G ratio of 3.02 and a beta of 1.45. Intuitive Surgical, Inc. has a 1-year low of $328.57 and a 1-year high of $603.88.
Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 EPS for the quarter, beating the consensus estimate of $2.65 by $0.35. The company had revenue of $3.05 billion during the quarter, compared to analysts' expectations of $2.91 billion. Intuitive Surgical had a net margin of 25.54% and a return on equity of 18.17%. The business's revenue for the quarter was up 21.7% compared to the same quarter last year. During the same period in the previous year, the company earned $2.40 EPS. As a group, equities research analysts anticipate that Intuitive Surgical, Inc. will post 9.37 earnings per share for the current fiscal year.
Key Headlines Impacting Intuitive Surgical
Investors following ISRG have been watching these headlines:
- Positive Sentiment: A recent earnings-focused report highlighted 25% adjusted EPS growth to $3, supported by broader robotic-platform adoption and AI-related innovation. Revenue growth has also been strong. ISRG EPS climbs 25%
- Neutral Sentiment: Another analysis argues ISRG may be near fair value despite revenue growth, focusing on whether future cash flows justify its valuation as competition increases and new robotic platforms enter the market. This valuation debate could limit enthusiasm for the shares. ISRG stock may be near fair value
- Negative Sentiment: The earnings commentary also noted rising research and development costs and a litigation settlement, potential headwinds to profitability even as adjusted EPS increased. Zacks earnings analysis
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on ISRG shares. Barclays reaffirmed an "overweight" rating and set a $500.00 target price (up from $485.00) on shares of Intuitive Surgical in a research note on Wednesday, October 21st. Zacks Research raised Intuitive Surgical from a "hold" rating to a "strong-buy" rating in a report on Thursday, October 22nd. Piper Sandler reissued an "overweight" rating on shares of Intuitive Surgical in a report on Friday, August 21st. Raymond James Financial restated an "outperform" rating and set a $480.00 price objective on shares of Intuitive Surgical in a research report on Wednesday, October 21st. Finally, Wells Fargo & Company reaffirmed an "overweight" rating and issued a $486.00 target price (down from $487.00) on shares of Intuitive Surgical in a report on Wednesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $495.90.
View Our Latest Report on ISRG
Hedge Funds Weigh In On Intuitive Surgical
Hedge funds have recently made changes to their positions in the stock. Fi3 FINANCIAL ADVISORS LLC increased its position in Intuitive Surgical by 19.1% during the 3rd quarter. Fi3 FINANCIAL ADVISORS LLC now owns 1,002 shares of the medical equipment provider's stock worth $407,000 after purchasing an additional 161 shares during the period. Heartland Bank & Trust Co lifted its holdings in shares of Intuitive Surgical by 4.7% in the 3rd quarter. Heartland Bank & Trust Co now owns 2,082 shares of the medical equipment provider's stock valued at $847,000 after buying an additional 94 shares during the period. Harbor Advisors LLC acquired a new stake in Intuitive Surgical in the third quarter valued at $203,000. Innovator Capital Management LLC purchased a new stake in shares of Intuitive Surgical during the 3rd quarter worth $7,982,000. Finally, Brown Financial Advisors grew its stake in shares of Intuitive Surgical by 25.5% during the 3rd quarter. Brown Financial Advisors now owns 2,877 shares of the medical equipment provider's stock worth $1,170,000 after purchasing an additional 584 shares during the period. 83.64% of the stock is currently owned by institutional investors.
Intuitive Surgical Company Profile
(
Get Free Report)
Intuitive Surgical develops, manufactures and markets robotic-assisted systems for minimally invasive procedures. Its products include da Vinci surgical systems, which allow surgeons to control instruments and a high-definition vision system from a console, as well as the Ion endoluminal system, designed to assist with minimally invasive lung biopsies. The company also provides instruments, accessories, training and support services for its systems. Its technology is used in a range of surgical specialties, including urology, general surgery and gynecology.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Intuitive Surgical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intuitive Surgical wasn't on the list.
While Intuitive Surgical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.